Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab for late antibody-mediated rejection after kidney transplant
2026-526239-20-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in humoral rejection comparing Mezagitamab with Placebo comparator (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of related treatment-emergent adverse events and 4 more. Planned start Oct 2026; status: authorised.
02
Drugs
mezagitamab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2026-526239-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526239-20-00.